Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus

被引:11
作者
Mahmoud, Maha M. [1 ]
Afifi, Marwa M. [2 ]
机构
[1] Univ Alexandria, Fac Dent, Oral Med Periodontol Radiol & Diag, Alexandria, Egypt
[2] Univ Alexandria, Fac Dent, Oral Pathol, Alexandria, Egypt
关键词
angiogenesis; bevacizumab; IL-8; oral lichen planus; VEGF; ENDOTHELIAL GROWTH-FACTOR; COLLAGEN-INDUCED ARTHRITIS; INTRAVITREAL BEVACIZUMAB; FACTOR VEGF; TNF-ALPHA; AVASTIN; EFFICACY; CANCER; INHIBITION; BIOLOGY;
D O I
10.1111/eos.12251
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Oral lichen planus (OLP), a mucocutaneous chronic inflammatory disease, is conventionally managed using topical corticosteroid therapy. Given the fact that OLP is strongly linked to angiogenesis, anti-angiogenic drugs, such as bevacizumab, might be introduced as an alternative treatment for contraindicated, non-responsive patients. The aim of the present study was to report the short-term effectiveness and safety of intralesional bevacizumab injection in the management of atrophic/erosive OLP. A case series study was conducted in patients with atrophic/erosive OLP in the buccal mucosa, assigned to receive either 2.5mg of bevacizumab, by intralesional injection (n=20, test), or topical 0.1% triamcinolone acetonide ointment (n=20, control). The size, score, and pain intensity of the lesions were assessed pre- and post-treatment. Tissue biopsies were collected for histopathologic, immunohistochemical, and ultrastructural examination. After 1wk, the test group had significant reductions both in lesion seize and in pain scores compared with controls. A marked decrease in vascular endothelial growth factor (VEGF) and interleukin-8 immunoexpression was noted in tissue biopsies from bevacizumab-treated lesions compared with control lesions. Furthermore, ultrastructural examination of OLP tissue specimens revealed significant healing signs associated with bevacizumab treatment. Short-term data suggest that intralesional bevacizumab injection effectively and safely achieved resolution of atrophic/erosive OLP lesions without disease exacerbations during a 3-month follow-up period.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 50 条
[11]   Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy [J].
Zhang, Xiao-Pei ;
Sun, Jian-Guo ;
Yao, Jin ;
Shan, Kun ;
Liu, Bai-Hui ;
Yao, Mu-Di ;
Ge, Hui-Min ;
Jiang, Qin ;
Zhao, Chen ;
Yan, Biao .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 :1056-1063
[12]   Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors [J].
Dey, Nandini ;
De, Pradip ;
Brian, Leyland-Jones .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (10) :1675-1698
[13]   Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy [J].
Ferreira, Natalia N. ;
Ferreira, Leonardo M. B. ;
Miranda-Goncalves, Vera ;
Reis, Rui M. ;
Seraphim, Thiago V. ;
Borges, Julio Cesar ;
Baltazar, Fatima ;
Gremiao, Maria Palmira D. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2017, 119 :271-282
[14]   Anti-angiogenic Therapy: Concept to Clinic [J].
Young, Robin J. ;
Reed, Malcolm W. R. .
MICROCIRCULATION, 2012, 19 (02) :115-125
[15]   Biomarkers for Anti-Angiogenic Therapy in Cancer [J].
Wehland, Markus ;
Bauer, Johann ;
Magnusson, Nils E. ;
Infanger, Manfred ;
Grimm, Daniela .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (05) :9338-9364
[16]   Anti-Angiogenic Cancer Therapy Updates [J].
Ali, A. M. ;
Toi, M. ;
Ueno, T. .
CURRENT MOLECULAR MEDICINE, 2009, 9 (08) :954-966
[17]   Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers [J].
Iwasaki, Junko ;
Nihira, Shin-ichi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (09) :543-551
[18]   Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab [J].
Neel Patel ;
Sarah Able ;
Danny Allen ;
Emmanouil Fokas ;
Bart Cornelissen ;
Fergus V. Gleeson ;
Adrian L. Harris ;
Katherine A. Vallis .
EJNMMI Research, 7
[19]   Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab [J].
Philip Weißhardt ;
Tanja Trarbach ;
Jan Dürig ;
Andreas Paul ;
Henning Reis ;
Derya Tilki ;
Inna Miroschnik ;
Süleyman Ergün ;
Diana Klein .
Histochemistry and Cell Biology, 2012, 137 :391-401
[20]   Anti-angiogenic therapy for osteosarcoma [J].
Quan, Gerald M. Y. ;
Choong, Peter F. M. .
CANCER AND METASTASIS REVIEWS, 2006, 25 (04) :707-713